Stock Events

Evotec 

$3.21
249
-$0.05-1.53% Today

Statistics

Day High
-
Day Low
-
52W High
12.4
52W Low
2.85
Volume
49,381
Avg. Volume
129,265
Mkt Cap
1.13B
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

6
NOV
Earnings
 

Dividends

0%Dividend Yield
Jan 19
$0.07
Dec 18
$0.05
Nov 18
$0.05
Oct 18
$0.05
Sep 18
$0.05
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

6NovConfirmed
Q3 2022
Q1 2023
Q2 2023
Q3 2023
Q1 2024
Q2 2024
Next
-0.58
-0.39
-0.19
0
Expected EPS
-0.0438868
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EVO. It's not an investment recommendation.
Alphabet
71300
GOOGL
Apple
62568
AAPL
Microsoft
58318
MSFT
Amazon
53735
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.07B
CRISPR Therapeutics is involved in gene editing, a field that overlaps with Evotec's drug discovery platforms, making them direct competitors in the biotech innovation space.
Vertex Pharmaceuticals
VRTX
Mkt Cap123.21B
Vertex Pharmaceuticals focuses on creating new treatments for serious diseases, directly competing with Evotec's drug discovery and development services.
Novartis
NVS
Mkt Cap251.19B
Novartis is a large pharmaceutical company that competes with Evotec in the drug discovery and development sector, particularly in the development of novel therapeutics.
Gilead Sciences
GILD
Mkt Cap91.86B
Gilead Sciences is a biopharmaceutical company that competes with Evotec in the area of drug discovery, development, and commercialization, especially in the fields of antiviral drugs.
AMGEN
AMGN
Mkt Cap172.72B
Amgen is a biotechnology firm focusing on human therapeutics, competing with Evotec in drug discovery and development, particularly in the biotech sector.
Regeneron Pharmaceuticals
REGN
Mkt Cap127.86B
Regeneron Pharmaceuticals is known for its innovation in biopharmaceuticals, competing with Evotec in drug discovery and development, especially in the area of monoclonal antibodies.
Biomarin Pharmaceutical
BMRN
Mkt Cap17B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and rare genetic diseases, competing with Evotec in the niche market of rare diseases drug discovery.
Alnylam Pharmaceuticals
ALNY
Mkt Cap34.6B
Alnylam Pharmaceuticals is a leader in RNAi therapeutics, competing with Evotec in the development of novel RNA-based therapies.
Beam Therapeutics
BEAM
Mkt Cap2.01B
Beam Therapeutics competes with Evotec in the cutting-edge field of gene editing, specifically using base editing technology to develop precision genetic medicines.

Analyst Ratings

8$Average Price Target
The highest estimate is $8.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Miscellaneous
Investment Trusts/Mutual Funds
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Show more...
CEO
Werner Lanthaler
Employees
5022
Country
US
ISIN
US30050E1055
WKN
000A0QZ3J

Listings

MI
IT
1EVT.MI
OTCM
US
EVOTF
VI
AT
EVT.VI
XETRA
DE
EVT.XETRA